Pediatr. praxi. 2016;17(6):344-347 | DOI: 10.36290/ped.2016.076

News in treatment of inflammatory bowel diseases in children

MUDr. Katarína Mitrová, Ph.D.
Pediatrická klinika FN v Motole, Praha

Inflammatory bowel diseases, which include Crohn’s disease and ulcerative colitis, can negatively affect child development and quality of life. Early age at diagnosis is associated with more severe disease course and higher complication rate. Appropriate and early treatment can prevent structural and irreversible changes of intestine.

Keywords: Crohn’s disease, ulcerative colitis, enteral nutrition, immunomodulators, biologic treatment

Published: December 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mitrová K. News in treatment of inflammatory bowel diseases in children. Pediatr. praxi. 2016;17(6):344-347. doi: 10.36290/ped.2016.076.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis. 2014; 8(10): 1179-1207. Go to original source... Go to PubMed...
    2. Grover Z, Muir R, Lewindon P. Exclusive enteral nutrition induces early clinical, mucosal and transmural remission in paediatric Crohn's disease. J Gastroenterol. 2014; 49(4): 638-645. Go to original source... Go to PubMed...
    3. Gupta K, Noble A, Kachelries KE, et al. A Novel Enteral Nutrition Protocol for the Treatment of Pediatric Crohn's Disease. Inflamm Bowel Dis 2013; 19: 1374-1378. Go to original source... Go to PubMed...
    4. Dziechciarz P, Horvath A, Shamir R, Szaiewska H. Meta-analysis: enteral nutrition in active Crohn's disease in children. Aliment Pharmacol Ther 2007;15: 795-806. Go to original source... Go to PubMed...
    5. Turner D, Levine A, Escher JC, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. JPGN 2012; 55: 340-361. Go to original source... Go to PubMed...
    6. Doporučení Pracovní skupiny dětské gastroenterologie a výživy ČPS pro diagnostiku a léčbu nespecifických střevních zánětů u dětí. ČS pediatrie 2012; 67: 1-48.
    7. Ford AC, Khan KJ, Achkar JP, et al. Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis. Am J Gastroenterol 2012; 107: 167-176. Go to original source... Go to PubMed...
    8. Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol 2004; 2: 731-743. Go to original source... Go to PubMed...
    9. Turner D, Grossman AB, Rosh JR, et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn disease. Am J Gastroenterol 2007; 102: 2804-2812. Go to original source... Go to PubMed...
    10. Hyams J, Crandall W, Kugathasan S, et al. REACH Study group: Induction and maintenance infliximab therapy for the treatment of moderate to severe Crohn's disease in children. Gastroenterology 2007; 132: 863-873. Go to original source... Go to PubMed...
    11. Hyams JS, Lerer T, Griffiths A, et al. Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol 2010; 105: 1430-1436. Go to original source... Go to PubMed...
    12. Hyams JS, et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterol. 2012; 143(2): 365-374. Go to original source... Go to PubMed...
    13. Russell RK, Wilson ML, Loganathan S, et al. A BSPGHAN survey of the effectiveness and safety of adalimumab in Children with Inflammatory Bowel Disease. Aliment Pharmacol Ther 2011; 33: 946-953. Go to original source... Go to PubMed...
    14. Volonaki E, Mutalib M, Kiparissi F, et al. Adalimumab as a second-line biological therapy in children with refractory ulcerative colitis. Eur J Gastroenterol Hepatol. 2015; 27(12): 1425-1428. Go to original source... Go to PubMed...
    15. Merras-Salmio L, Kolho KL. Golimumab Therapy in Six Patients with Severe Pediatric Onset Crohn's Disease. JPGN. 2016 Feb 15. [Epub ahead of print] Go to original source... Go to PubMed...
    16. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013; 369(8): 711-721. Go to original source... Go to PubMed...
    17. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013; 369(8): 699-710. Go to original source... Go to PubMed...
    18. Singh N, et al. Abstract 321. Presented at: Digestive Disease Week, May 16-19, 2015; Washington, D.C.
    19. Stein R, et al. Abstract 322. Presented at: Digestive Disease Week, May 16-19, 2015; Washington, D.C.
    20. Cameron FL, Garrick V, Russell RK. Ustekinumab in Treatment Refractory Paediatric Crohn's Disease. JPGN 2016; 62(3): e30. Go to original source... Go to PubMed...
    21. Levine, A, Turner D. Combined azithromycin and metronidazole therapy is effective in inducing remission in pediatric Crohn'sdisease. J Crohns Colitis 2011; 5(3): 222-226. Go to original source... Go to PubMed...
    22. Turner D, Levine A, Kolho KL, et al. Combination of oral antibiotics may be effective in severe pediatric ulcerative colitis: A preliminary report. J Crohns Colitis 2014; 8(11): 1464-1470. Go to original source... Go to PubMed...
    23. Fukuda Y, Matsui T, Suzuki Y, et al. Adsorptive granulocyte and monocyte apheresis for refractory Crohn's disease: an open multicenter prospective study. Journal of gastroenterology 2014; 39(12): 1158-1164. Go to original source... Go to PubMed...
    24. Cassinotti A, Annaloro C, Ardizzone S, et al. Autologous haematopoetic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease. Gut 2008; 57(2): 211-217. Go to original source... Go to PubMed...

    Return to the content


    Pediatrics for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.